Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, comments on whether the expanding knowledge around pre-malignant pathologies, namely clonal hematopoiesis of indeterminate potential (CHIP), may impact treatment approaches and clinical practice in patients with hematological malignancies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.